BICMG

Business Information Consulting & Management Group

The Future of Medical Technology by Abaan Merchant

images.jpg

The recent technological boom has revolutionized our lives by delivering endless information to our fingertips. Advancements in medicine have led to increasingly efficient means of providing patient health and care. From robotic surgery to telemedicine, patients and professionals are growing more reliant on technology to improve diagnoses, patient care, and quality of life. Recently developed technology has focused on allowing for an earlier diagnosis while increasing physician efficiency and healthcare accessibility.

Today’s medical advancements have become synonymous with “early prevention.” Medicine has traditionally focused on “tertiary prevention,” which aims to limit disability only after a disease has taken its toll on the body. This trend is a result of limitations in medicinal knowledge and equipment.

 This promotes a healthy lifestyle and aims to diagnose health problems before they can affect the body.

Medicinal technologies have also developed a “primitive intelligence” that assists healthcare professionals to better perform their work. For example, nearly all US healthcare institutions have now implemented a CDSS (Computerized Decision Support System). This system automatically integrates pertinent patient information as well as related evidence-based clinical practice guidelines and presents it to the physician. By reviewing the information in the collected documents in a matter of seconds, the CDSS can provide physicians with accurate diagnoses, recommendations, and treatment plans. Inspired by the success of the CDSS, new programs continue to be generated to increase healthcare efficiency and reduce human error.

The third and most transformative change has been the introduction of “portal technology” to patients. They now have greater control over their healthcare experiences by being able to easily and safely access their medical records. In recent years, devices tracking health statistics of individuals have seen an increase in usage. Nearly all major electronics companies are releasing their devices with built-in programs that can encourage and promote a healthy lifestyle. These applications can sum up recorded information such as sleep schedules, daily exercise, and nutrition. This can prove to be a useful insight for physicians by allowing them to suggest improvements in lifestyle choices based on the collected data.

Technological advancements continue to lay the foundation for a healthcare system without limits. Increasing accessibility and reducing cost and error are important points to focus on if we hope to provide the best quality of care. As technology continues to be developed, the burdens and restraints presented to us today will certainly fade.

 

Source: http://www.premedlife.com/feature-articles/the-future-of-medical-technology-5424/

FDA clears first medical accessory for the Apple Watch—an EKG sensor by Valentina Palladino

Plenty of studies boast about the medical possibilities of the Apple Watch, but Apple's wearable is a consumer device, not a medical one. However, the FDA just announced the clearing of the first medical Apple Watch accessory, AliveCor's Kardia…

Plenty of studies boast about the medical possibilities of the Apple Watch, but Apple's wearable is a consumer device, not a medical one. However, the FDA just announced the clearing of the first medical Apple Watch accessory, AliveCor's KardiaBand, which uses the wearable's heart rate technology and an attached sensor to provide EKG readings on the fly. An Apple Watch paired with a KardiaBand could provide users with an EKG reading in 30 seconds, detecting abnormal heart rhythm and atrial fibrillation and sending that information to a doctor for further analysis.

FURTHER READING

Apple, Fitbit, others work with FDA to pilot digital health software

The $199 device is an unassuming black band that attaches to the Apple Watch like other band accessories. On the band right below the Apple Watch module is the KardiaBand's silver sensor where users place their finger to take a reading. The Apple Watch's display shows the reading's data using a line graph that's similar to how the Apple Watch shows other heart rate data and informs the user if their heart rate is normal or abnormal.

AliveCor's new SmartRhythm technology takes a more personalized approach to the prevention technology the Apple Watch already has. Currently, Apple's wearable can alert you when your heart rate spikes, but SmartRhythm uses AliveCor's deep neural network and your history of heart rate data to determine a healthy and normal heart rate range for you in relation to your activity levels. If an abnormality is detected during the Apple Watch's continuous measurement of your heart rate, AliveCor and KardiaBand's app will prompt you to take an EKG reading. The Watch's display will then show the normal heart rate range that KardiaBand's technology estimated for you, the abnormal heart rate detected, and where the EKG reading falls in relation to that data.

The KardiaBand isn't AliveCor's first medical device—the company already sells KardiaMobile, a small, rectangular EKG reader that pairs with a mobile app that allows users to take quick EKG readings by laying two fingers on their sensor on the device. The KardiaBand makes this technology more discrete by making it into a tiny sensor that snaps into an Apple Watch band, making it accessible anywhere, anytime. EKG readers similar to KardiaMobile have been around for some time, but the KardiaBand is the first medical accessory cleared by the FDA for use with an Apple Watch.

The KardiaBand is relatively accessible at $199, and users can email and print EKG recordings for no extra cost. However, users must pay $99 per year for AliveCor's premium program if they want access to unlimited cloud storage and history, customized monthly reports shared with their doctor, and other perks.

The FDA has made an effort to collaborate with tech companies that want to make it easier to produce devices and software that consumers can use to monitor their health. Recently, Apple, Fitbit, Samsung, and Johnson & Johnson were announced as just a few of the companies participating in the FDA's precertification pilot program under its Digital Health Innovation Action Plan. All of the companies involved with this program will help the FDA set guidelines for approving health and medical software that devices can use. Instead of approving and further monitoring individual devices, the FDA appears to be more interested in the software that these devices run. The FDA will likely continue to monitor AliveCor's software for KardiaBand and any other consumer wearables it makes in the future.

 

Source: https://arstechnica.com/gadgets/2017/11/fda-approves-first-medical-accessory-for-the-apple-watch-an-ekg-sensor/

Medical technologies could save UK economy half a billion, report shows by

The report shows that the use of eight medical technologies could save the UK economy £476 million in reduced long-term health costs and benefit payments. The savings are equivalent to 20,000 nurses or 10.5 million GP visits.The technologies hi…

The report shows that the use of eight medical technologies could save the UK economy £476 million in reduced long-term health costs and benefit payments. The savings are equivalent to 20,000 nurses or 10.5 million GP visits.

The technologies highlighted in the report include coronary angioplasty, hip replacements, implantable cardiac defibrillators (ICDs), insulin pumps, diagnostics including sepsis, pain management, fibroid embolisation and wound care.

A fifth of the savings were estimated to come from coronary angioplasty, used to open blocked coronary arteries and restore blood flow to heart muscle. In 2015, almost 100,000 coronary angioplasty procedures were carried out, with 36% of in people under 60 years old. It’s estimated that 93% of patients in employment return to work after the procedure, becoming economically active again.

The savings in benefits for those returning back to work is equivalent to £123.3 million every year and is replicated every year for the rest of the patients’ working lives.

Other findings of the report show that 18,500 people are currently in work thanks to hip replacements, saving the economy £70 million every year; insulin pumps save the economy £13.8 million every year, helping people with diabetes manage their condition and £3 million every year is saved by patients returning to work with an ICD.

More so, greater access to fibroid embolisation could deliver £76 million a year in savings; better management of chronic wounds could deliver over £25 million in savings a year and £160 million could be saved by using rapid diagnosis to screen patients with suspected sepsis.  

Barbara Harpham, chair of the Medical Technology Group, said: “Medical technology has an enormous impact, both in terms of the quality of life that it offers patients and in the cost savings to the health service and the wider economy. Very often a single procedure can get a patient back to work or caring for their family and can instantly eliminate thousands of pounds in longer term treatment or unplanned admissions. In fact, we have not yet tapped into the full potential of all the medical technology currently available.

She added: “The trouble is that the upfront cost of medical technology often means patient access is being limited and cheaper short-term solutions being chosen; in other words, a false economy.

“With the NHS budget under increasing pressure, it’s time we rethink the approach to rationing medical treatments that gives people back their lives. It may look good on paper in this budget year, but doesn’t benefit patients and costs the health service more in the long run.”

 

Source: https://www.medicalplasticsnews.com/news/medical-technologies-could-save-uk/

The future of medical robotics by Jeremy Russell

There is a quiet robotic revolution occurring in the health sector that will prove crucial in an age of austerity, ageing and expanding populations, and medical staff shortages.    With its once sky-high cost, the economics of advance…

There is a quiet robotic revolution occurring in the health sector that will prove crucial in an age of austerity, ageing and expanding populations, and medical staff shortages.    

With its once sky-high cost, the economics of advanced medical technology did not allow for any fast integration into our cash-strapped public hospitals or even the better-off private institutions.   

But with gradually-declining running costs and healthcare leaders searching for new means of efficiency, we can expect to see more and more robotic systems in our hospitals.    

In fact, if you experience surgery in the future, chances are that your surgeon will be accompanied by a robotic assistant. With pinpoint precision, remarkable Artificial Intelligence (A.I.) and advanced algorithms, the presence of a robot will make your operation safer, faster and more hygienic.   

By providing surgical and other assistance to hospitals, medical robotics are already bringing down the cost of healthcare, eliminating human error, streamlining operating theatres, reducing operating time, and, crucially, freeing-up staff for more pressing matters.    

However, the uptake of such technology must be accelerated.     

Should current trends continue, the global needs-based shortage of health-care workers is projected to be still more than 14 million in 2030, according to World Health Organization estimates.      

But thought leaders like Dr. Bertalan Mesko, PhD, founder of the Medical Futurist website believe that technology will be the key to such challenges. Mesko predicts that methods of automation – such as A.I. robotics and 3D printing – will help to make healthcare sustainable and much more efficient in the future.      

In England alone, recent research showed that NHS hospitals could undertake 17 per cent (280,000) more non-emergency operating procedures every year with better-organised operating theatre schedules.   

The research, which analysed 2016 data collected from operating theatres in 100 NHS Trusts in England revealed that more than two hours a day are wasted on average.   

This suggests that operating theatres are significantly underutilised, with each procedure becoming costlier as a result.   

Such underperformance can be devastating in rocky periods. Leading medics recently warned that thousands of NHS operations could be cancelled for months this winter due to bed and staff shortages.      

So how fast will the medical sector embrace these technologies? And, what might they look like?    

Mechanical medical assistants, of course, do already exist, and in many different incarnations.  For example, UWE Bristol researchers at the Bristol Robotics Laboratory (BRL), a collaboration between the University of the West of England and the University of Bristol are creating new robotic tools and devices to be used semi-automatically under the supervision of surgeons during invasive medical procedures.      

BRL’s Dr Sanja Dogramadzi, who researches the use of robotic technologies to repair complex joint fractures, believes these tools have the potential to aid orthopaedic, abdominal and cardiovascular surgery. “By using minimally invasive access to organs and tissues, robotic tools can help to reduce trauma, speed up recovery and minimise costs.” she said.      

In her field, small robotic tools can be used to perform closed-joint reduction “with minimal invasion”. This alternative to the current open-joint surgery used to treat these types of fractures avoids the increased risk of infections and tissue failures, which can be a major risk with such invasive surgery.      

On a larger scale, Google is now working with Johnson and Johnson’s medical device company, Ethicon to develop A.I. surgical robots to assist surgeons during invasive operations. The tech giant, which will provide the software, believes it can use the machine vision and image analysis it has developed for self-driving cars and other ventures.  

The partnership will seek to use advanced imaging and sensors to assist surgeons by highlighting blood vessels, nerve cells, tumour margins or other important structures that could be hard to discern in tissue by eye or on a screen, the Guardian reported.  

The technology will also incorporate augmented reality to combine the numerous feeds of information currently spread across multiple monitors.

Other existing robotic alternatives such as the Da Vinci Surgical System use a magnified 3D high-definition vision system with tiny flexible instruments far more maneuverable than the human hand. This system eases and enhances a surgeon’s ability to operate safely and efficiently, yet has been limited in its use by high running costs.       

OR Productivity’s FreeHand system holds and manipulates laparoscopes and cameras during keyhole surgical procedures, and provides a rock-steady image. It also eliminates the need for at least one camera-holding medical assistant, and in-turn brings down the procedural costs.   

FreeHand is in talks with partners to combine expertise and build a full low-cost robotic system for laparoscopic surgery. This could use standalone products, and also enable much more expensive products, such as cameras and surgical robotic systems, to deliver their full potential benefits to patients.  

Robotic and technological systems will provide safer and faster operations to benefit both patients and surgeons, as well as lower costs for health service providers. Could this be the end of hospital waiting lists?        

For patients in particular, these technological advances will bring a greater peace of mind due to the reduced risk of human error in healthcare, as well as faster recovery times and even smaller surgical scars.      

Despite the increase in medical robotics, we are not yet within the realms of seeing surgeons made redundant by robots. However, rapid advancements in technology repeatedly remind us to rule-out no possibilities.     

Market projections appear to predict that robotic surgery is winning the economic argument. The Surgical Robotics Market was evaluated at $3bn in 2014, and is expected to double to $6bn by 2020, according to Allied Market Research. And due to a growing demand for minimally invasive procedures, the global market for laparoscopic devices alone is projected to reach $12.3bn by 2024.  

So as robotics – in all sectors - become more and more advanced, we may well need mass-retraining of workers and/or the life raft of a citizen’s income, and as Joshua M. Brown, the influential New York City financial advisor predicts, the simple answer is to invest in the very technology driving these radical changes: “Just own the damn robots”, he believes, is the solution.    

 

Source: https://www.itproportal.com/features/the-future-of-medical-robotics/

Medical 'pen' can detect cancer in 10 seconds by Brett Molina

It might look like a stylus, but it's capable of much more than just writing.

Researchers at the University of Texas at Austin created a medical "pen" that can detect cancer in roughly 10 seconds.

The MasSpec Pen is a handheld device resembling a stylus, and can identify cancerous tissue during surgery. Tests performed by researchers on tissues removed from 253 human cancer patients found the device was accurate more than 96% of the time.

“If you talk to cancer patients after surgery, one of the first things many will say is 'I hope the surgeon got all the cancer out,'" said Livia Schiavinato Eberlin, assistant professor of chemistry at UT Austin who designed the study, in a statement. "It’s just heartbreaking when that’s not the case. But our technology could vastly improve the odds that surgeons really do remove every last trace of cancer during surgery."

 

Researchers are working to secure patents for the technology, which they expect to test during oncologic surgeries in 2018.

The pen releases a drop of water on the tissue, allowing small molecules to migrate into the drop. The water is then pulled back into the device and analyzed using a mass spectrometer. On a computer screen, doctors will be able to read whether the issue is normal or cancerous.

"Any time we can offer the patient a more precise surgery, a quicker surgery or a safer surgery, that’s something we want to do," said James Suliburk, head of endocrine surgery at Baylor College of Medicine who worked on the project. "This technology does all three."

 

 

Source: https://www.usatoday.com/story/tech/news/2017/11/22/medical-pen-can-detect-cancer-10-seconds/884231001/

Irony: First FDA Approved Digital Pill Tracks Schizophrenic Patients by Teodora Zareva

The FDA has approved the first pill with an embedded ingestible sensor that can track when, or if, a patient takes their medication. The sensor will be used with the drug Abilify MyCite—which is prescribed to treat schizophrenia, bi-polar disor…

The FDA has approved the first pill with an embedded ingestible sensor that can track when, or if, a patient takes their medication. The sensor will be used with the drug Abilify MyCite—which is prescribed to treat schizophrenia, bi-polar disorders and depression—and automatically shares data with doctors, caregivers, family members or anyone else the patient has pre-approved.

The sensor attempts to solve the problem of nonadherence. As it turns out, millions of patients don’t take their medications as prescribed, which leads to poor therapeutic outcomes and costs billions per year in avoidable health care costs. Ameet Sarpatwari, an instructor in medicine at Harvard Medical School, said for The New York Times that the digital pill “has the potential to improve public health,” especially for patients who want to take their medication but forget.

On the flip side, the constant monitoring may actually increase mistrust or make patients feel uncomfortable. Dr. Peter Kramer, a psychiatrist referred to the drug as “packaging a medication with a tattletale.”

Here’s how the ingestible sensor works with the drug. The sensor is the size of a “grain of sand” and is embedded within the pill at the point of manufacture. In addition to taking the pill, the patients are also required to wear a patch on their skin, which acts as an external sensor. The patch reads the signals sent from the ingested sensor, which is activated after the pill has interacted with stomach fluids. The information is then sent from the patch to an app installed on the patient’s phone. The patient can share (or stop sharing at any time) this information with others. 

Ironically, the FDA notes on their website that “the ability of the product to improve patient compliance with their treatment regimen has not been shown.” The choice of drug (one that treats schizophrenia) to feature the first sensor of this kind may also raise some eyebrows. As Dr. Jeffrey Lieberman, chairman of psychiatry at Columbia University and NewYork-Presbyterian Hospital, said:

“There’s an irony in it being given to people with mental disorders that can include delusions. It’s like a biomedical Big Brother.”

Still, the technology could have other potentially beneficial applications. It could be used, for example, in clinical trials to make sure that participants are following protocols correctly. It could also be used to track excessive opioid use - a problem that has been on the rise in the U.S.

In more controversial applications, taking a pill like this could be a requirement for releasing patients with certain type of psychiatric disorders. It is also not a stretch to see that insurers may take an interest in it and provide incentives to customers who use it.

 

Source: http://bigthink.com/design-for-good/fda-approves-a-pill-that-can-track-whether-or-not-you-take-it

Why GE Won’t Sell its Health IT Business by Our Thought Leaders

As John Flannery, the new CEO of GE takes on the task of sweeping cost-cutting at the industrial behemoth, recent market speculation has suggested he may be looking to offload GE’s Healthcare IT business. Here’s why we think this won’t happen.

Crumbling, but not to the core

GE’s health IT portfolio has been compiled from many acquisitions, creating a complex and sometimes disjointed product set. At its center is a core set of software and services focused on clinical IT. GE’s products that support medical imaging and care delivery management (particularly in perinatal and perioperative applications) are well established, often sold in combination with GE’s leading position in medical imaging hardware and clinical care devices. Despite the odd hiccup, such as ongoing problems with its viewing software integration, this core clinical IT product set has been relatively successful.

 

It is outside of the core clinical IT business that GE has had significant issues. The grand vision to offer an “all you can eat” integrated solution for enterprise healthcare IT was a bold, but risky play. To achieve this, GE acquired a multitude of brands, expanding into markets such as workforce management, financial management, population health management and digital pathology, while also competing in one of the most cut-throat markets of all, acute EMR in North America.

The result? An unceremonious exit from the acute EMR market, limited integration between legacy business units and products and mothballing of the digital pathology unit at significant loss. Not to mention a weakened focus on its core clinical IT products, brininging with it the risk of falling behind major competitors Philips Healthcare and Siemens Healthineers. So why isn’t the new CEO looking to cut his losses?  

GE’s installed base of health IT customers is large and complex

Extracting the whole GE Healthcare IT business unit, under the brand Centricity, would be no easy feat. Many of GE’s IT deals are woven into equipment and professional service deals, often spanning multi-year engagements in diverse international markets. In more mature markets, such as North America and Western Europe, this approach has allowed GE to be aggressive on pricing and maintain its installed base, especially in the mid and large-scale provider market.

Such complexity could also scare off potential acquirers, of which there are few with the scale, deep-pockets and boldness required to make such a complex deal work. Moreover, in many areas outside of core clinical IT, GE is only a minor player. Sectors such as financial and operational administration are becoming more entrenched and consolidated, with a few large vendors dominating. Therefore, any acquirer would most likely want to offload these product lines, though the return on investment would be limited in an increasingly commodotised market.

Even if a buyer could be found, we think there is little momentum in the GE executive boardroom to sell. Why? Because offloading the health IT business would remove a critical aspect of GE’s wider healthcare business strategy.

Leave the paper pushing to the “experts”

While not immediately apparent on the surface, GE has grand ambitions for its healthcare business. It wants to become the central clinical partner to health providers, around which all clinical data and clinical hardware operates.

Most health providers now understand that no single vendor can offer all the capability and complexity that a large enterprise healthcare provider requires. Large electronic health record (EHR) vendors have continued to push the “one vendor” message. Yet, most specialise in handling administration, operational and financial systems and only really cater for a small proportion of all the software and services that providers require. Backing this up, recent estimates suggest on average as much as 70 percent of the data generated by a hospital remains outside of the EHR system.

This leaves room at most providers for a central clinical IT partner that can act as the lynchpin in creating, managing and analyzing clinical and diagnostic data. GE has already made this clear, at least in principle, with its GE Health Cloud product strategy. In becoming the central part of an open-source “ecosystem” of clinical tools and specialist partners, GE believes it can cement itself as a long-term partner for its customer.

GE will bring expertise in device hardware, clinical IT and professional services, with additional third-parties offering specialist tools, analytics and capabilities in areas where GE does not have capability in-house. GE is not alone in this strategy; Philips Healthcare has also undergone a drastic shedding of fringe products to focus solely on health and care, with a similar central partner strategy; Siemens is also looking to achieve and fund the same transformation by unshackling its Healthineers business unit with a forthcoming IPO, allowing greater flexibility for partnerships.

All the pieces of the clinical IT puzzle

Perhaps most surprising about the recent rumors is that GE has almost all the critical pieces required to make such a strategy successful, in-house already. If GE looks to refocus towards its core clinical IT business lines, it has the capabilities required for success. The four big trends driving market innovation and demand are:

– Personalized medicine (including use of genetics and advanced testing)

– Integrated clinical care (connecting care systems and clinical disciplines)

– Operational efficiency (use of analytics to save time and to reduce the overall cost of care)

– Machine learning and big data (learning from health data to make all the above faster and smarter to allow greater predictability and prevention)

GE has capabilities and a position that well aligns to this market direction:

– A strong life sciences division including capability in genetics, drug discovery and cell therapy (personalized medicine)

– Portfolio of core clinical IT software and services for acute and ambulatory diagnostics and clinical review, including population health management (integrated clinical care)

– Lengthy experience in capital equipment management and service, plus new initiatives focused on clinical command control centres and analytics to drive care management operational efficiency)

– Predictive analytics platform to drive progression of machine learning capabilities to support GE healthcare products and partners (machine learning and big data)   

Perhaps then, the question of whether to sell the healthcare IT business is not really the right one for GE. Sure, spinning off some parts of the business will save operational cost and appease investors in the short-term, but it will do little to help GE with its wider healthcare strategy. Instead the problem could be a far greater and graver one. It is also a problem with which the new CEO should be well-versed following his tenure as head of the GE healthcare business:

Why, when GE has all the requisite parts, is GE struggling to create a coherent and integrated IT business that can capitalize on the new demands of 21st century healthcare? 

 

Source: http://hitconsultant.net/2017/11/20/ge-healthcare-wont-sell-health-business/

Exponential Medicine And The Joy Of Technology by John Nosta

Recently I attended the Exponential Medicine meeting in California. Led by the physician-innovator Daniel Kraft MD, the conference is an amazing collection of thinkers, doers and visionaries that focuses on the convergence of technology and medicine.

Certainly, it's a science-based meeting that addresses the role technology can play in the diagnosis and management of disease. Some even say XMed is a bit like drinking out of an information fire hose. And while medical technology and innovation stand at the center of this popular meeting, there was something else that captured both my head and my heart.

Beyond the impressive contributions of leading scientists, clinicians and patients, there was as an undercurrent of humanity and empathy that seems to push the binary and biologic to a unique and powerful place. Today, technology is empowering physicians, caregivers and patients with a sense of purpose and compassion. And the Exponential Medicine meeting is emerging as a catalyst for these important changes.

A powerful tool to drive empathy. Imagine having Parkinson's disease. With this fascinating device pioneered by Klick Health, it's possible to reproduce the actual movement disorder in your own arm. What results is a direct experience that fosters understanding and empathy. The video is a testament to technology and humanity.

Connecting the world with virtual reality. Surgeon and innovator Shafi Ahmed is an expert in the use of virtual reality in the operating room. His work has expanded the OR beyond the tiled walls to countless hospitals and medical schools around the world. Ahmed is changing the way we teach surgery and leveraging technology to touch the minds of student who otherwise might never have the chance to experience world-class innovations and techniques. His recent TEDx talk, "Connecting A Billion Minds," captures this perfectly. 

 

 

A father's son and compassionate physician. Dr. Alan Greene, a pediatrician and internet innovator, captured the audience with his discussion that focused on the end and the beginning of life, including his father's death—what Greene refers to as "the most profound and important moments in a man's life." Greene spoke on the power of "why" and the value of "presence" in today's hectic world.

A stem cell pioneer who is driving discovery from his wheelchair. Perched upon his unique vantage point on stem cell therapy, Roman Reed told us a very personal story about his quest to drive innovation in the battle to cure his—and every—spinal cord injury patient. Reed is the founder of StemRemedium, a private equity firm that combines world-class partnerships among scientists, industry and finance to drive innovation in stem cell therapy.

A musical interlude from a recipient of two double lung transplants. At XMed, science and technology doesn't stop, even when there's a musical break. Charity Sunshine Tillman-Dick provided both her beautiful voice and compelling story. A two-time, double lung transplant recipient and vocal soprano, Tillman-Dick transfixed the audience with her voice and story of perseverance that's also captured in her new book The Encore: A Memory in Three Acts

A personal journey made very public. Jennifer Brea is an active Harvard PhD student about to marry the love of her life when suddenly her body starts failing her. Hoping to shed light on her strange symptoms, Jennifer grabs a camera and films the darkest moments unfolding before her eyes as she is derailed by myalgic encephalomyelitis (M.E. and commonly known as Chronic Fatigue Syndrome), a mysterious illness some still believe is “all in your head.” On stage at XMed and in an on-site screening of her film Unrest, Brea put a spotlight on her personal journey and this complex condition.

There's no shortage of technological innovations at XMed. This meeting is well known for its content, faculty, and attendees. And 2017 was certainly no exception. But more than ever, humanity and empathy were themes that were masterfully weaved throughout the conference. Humanity and technology came together to help focus and inspire the attendees and presenters. Tears, laughs and inspiration define the four conference days and the world is a little better off because of it.

The entire conference is now available online. It's a compelling view for those in medicine and technology. But many others — from patients to caregivers — can appreciate to power of this conference to touch our hearts and minds to drive these life-saving innovations forward. 

 

Source: https://www.forbes.com/sites/johnnosta/2017/11/13/exponential-medicine-and-the-joy-of-technology/#12d2ffb41db7

Exponential Medicine And The Joy Of Technology by John Nosta

Recently I attended the Exponential Medicine meeting in California. Led by the physician-innovator Daniel Kraft MD, the conference is an amazing collection of thinkers, doers and visionaries that focuses on the convergence of technology and med…

Recently I attended the Exponential Medicine meeting in California. Led by the physician-innovator Daniel Kraft MD, the conference is an amazing collection of thinkers, doers and visionaries that focuses on the convergence of technology and medicine.

Certainly, it's a science-based meeting that addresses the role technology can play in the diagnosis and management of disease. Some even say XMed is a bit like drinking out of an information fire hose. And while medical technology and innovation stand at the center of this popular meeting, there was something else that captured both my head and my heart.

Beyond the impressive contributions of leading scientists, clinicians and patients, there was as an undercurrent of humanity and empathy that seems to push the binary and biologic to a unique and powerful place. Today, technology is empowering physicians, caregivers and patients with a sense of purpose and compassion. And the Exponential Medicine meeting is emerging as a catalyst for these important changes.

 

A powerful tool to drive empathy. Imagine having Parkinson's disease. With this fascinating device pioneered by Klick Health, it's possible to reproduce the actual movement disorder in your own arm. What results is a direct experience that fosters understanding and empathy. The video is a testament to technology and humanity.

 

Connecting the world with virtual reality. Surgeon and innovator Shafi Ahmed is an expert in the use of virtual reality in the operating room. His work has expanded the OR beyond the tiled walls to countless hospitals and medical schools around the world. Ahmed is changing the way we teach surgery and leveraging technology to touch the minds of student who otherwise might never have the chance to experience world-class innovations and techniques. His recent TEDx talk, "Connecting A Billion Minds," captures this perfectly. 

A father's son and compassionate physician. Dr. Alan Greene, a pediatrician and internet innovator, captured the audience with his discussion that focused on the end and the beginning of life, including his father's death—what Greene refers to as "the most profound and important moments in a man's life." Greene spoke on the power of "why" and the value of "presence" in today's hectic world.

A stem cell pioneer who is driving discovery from his wheelchair. Perched upon his unique vantage point on stem cell therapy, Roman Reed told us a very personal story about his quest to drive innovation in the battle to cure his—and every—spinal cord injury patient. Reed is the founder of StemRemedium, a private equity firm that combines world-class partnerships among scientists, industry and finance to drive innovation in stem cell therapy.

A musical interlude from a recipient of two double lung transplants. At XMed, science and technology doesn't stop, even when there's a musical break. Charity Sunshine Tillman-Dick provided both her beautiful voice and compelling story. A two-time, double lung transplant recipient and vocal soprano, Tillman-Dick transfixed the audience with her voice and story of perseverance that's also captured in her new book The Encore: A Memory in Three Acts

A personal journey made very public. Jennifer Brea is an active Harvard PhD student about to marry the love of her life when suddenly her body starts failing her. Hoping to shed light on her strange symptoms, Jennifer grabs a camera and films the darkest moments unfolding before her eyes as she is derailed by myalgic encephalomyelitis (M.E. and commonly known as Chronic Fatigue Syndrome), a mysterious illness some still believe is “all in your head.” On stage at XMed and in an on-site screening of her film Unrest, Brea put a spotlight on her personal journey and this complex condition.

There's no shortage of technological innovations at XMed. This meeting is well known for its content, faculty, and attendees. And 2017 was certainly no exception. But more than ever, humanity and empathy were themes that were masterfully weaved throughout the conference. Humanity and technology came together to help focus and inspire the attendees and presenters. Tears, laughs and inspiration define the four conference days and the world is a little better off because of it.

The entire conference is now available online. It's a compelling view for those in medicine and technology. But many others — from patients to caregivers — can appreciate to power of this conference to touch our hearts and minds to drive these life-saving innovations forward.

 

Source: https://www.forbes.com/sites/johnnosta/2017/11/13/exponential-medicine-and-the-joy-of-technology/#1e792d7e1db7

Innovations in heart tech: 5 things standing between now and better medical technology by Anicka Slachta

image001[1].png

From pocket-sized electrocardiograms to watches that measure blood glucose levels, the field of medical technology is rapidly evolving. But these innovations, though oftentimes successful, aren’t necessarily living up to what scientists want them to be, according to presenters at the American Heart Association’s Scientific Sessions 2017.

A group of doctors who deal with technology and innovation in the medical landscape spoke to both the strengths and weaknesses of device development in a field that’s more demanding of its researchers and engineers than ever before, expanding on ways we can eliminate current barriers and advance medical technologies to better serve patient—and provider—populations.

These are five takeaways:

1. Scientists should be assembling more diverse development teams.

Most researchers working on new medical technology are often field-specialized and tech-savvy, Stanford University’s Paul J. Wang, MD, said at the conference. While this is both helpful and necessary, limiting a design team to individuals of similar expertise could be a mistake.

“It’s difficult to introduce new technology,” he said. “Who invents? Do clinicians invent?”

The answer to that question is overwhelmingly “no,” he said. While a fraction of scientists on these projects are clinicians, Wang said he thinks it’s necessary to include doctors and engineers from other disciplines in the innovation process.

Not enough people are working on medical technology solutions, he said, and those who are find themselves at a loss for adequate funding. He said he believes building a community of innovators through offering specialized training paths, seed funding and competitions could be the first step to better collaboration.

2. We need to bridge the Valley of Death.

Scientists attempting to contribute to medicine’s new technological landscape will likely find themselves at an impasse—a gap in their road to innovation known as the “Valley of Death.” While conceptual research is often generously funded—mostly by the National Institutes of Health, Wang said—there remains a chasm between that initial stage and FDA approval, clinical development and the launch of a device.

Wang said this results from a lack of consistent funding during the prototype design and preclinical stages of development, which are hugely important but remain unfunded by national groups like NIH or Big Pharma.

Finding good money flow for early stages of device development is a “monumental task, and has become a lot more difficult recently,” Wang said.

He said advising and assisting researchers in learning about funding sources, working with industry and grant providers to create funding paths and creating incubators could all be shifts the industry could make if it wants to continue to fuel innovation.

3. Patients want to self-monitor with wearable technology.

Smartwatches, activity monitors and FitBits are just a handful of devices that have been introduced to a consumer market that’s increasingly demanding at-home, on-the-go medical monitoring. These high-grade, wearable technologies have opened a world of new treatment possibilities for doctors, but they aren’t without their limitations.

Watches can now monitor pulse, blood pressure, temperature, activity, hydration status, sleep stages, stress and even blood glucose levels, Jagmeet Singh, MD, PhD, said, and those features are helpful for remote management of conditions like atrial fibrillation. For example, Singh said, AliveCor’s Kardia—a portable EKG—allows him to monitor his Romanian patient’s AF from Boston.

“These are devices that connect us with our patients, and connect their lives with us,” he said.

Wearables also have the ability, through various sensors, to collect information that could raise red flags for physicians and prevent future heart failure hospitalizations in patients.

However, he said, there’s currently a shift in how remote monitoring works–while information from wearable devices has in the past been documented and sent straight to a patient’s doctor, those numbers are increasingly being passed on to lower-level physicians and assistants. The goal, he said, is that numbers collected from wearable devices will be transmitted to smartphones, where patients themselves will be able to view the statistics and intervene on their own.

To make the most of wearables, Singh said, we need to create more and better sensors, generate more accurate data, build reliability and change the culture of care.

4. Doctors need to adopt a continuous care model rather than the current episodic routine.

Healthcare right now is episodic and transactional, Singh said, which isn’t ideal. A continuous care model would be more preventative, allowing doctors to monitor patients constantly through wearable or implantable devices and intervene appropriately instead of waiting for a three- or six-month checkup.

We need to digitize humans like we do cars, Singh said—they have check engine lights and alert us when they need an oil change. With implantable devices, scientists can monitor a patient’s body more closely than ever before.

“Every organ system has the ability to be digitized,” he said. “There are sensors that can be implanted with every organ.”

We’ve progressed as a scientific community from basic heart monitors to devices that can monitor heart sounds, chemicals and biomarkers, he said. But to use these technologies successfully, there needs to be a shift in how doctors approach caring for their patients.

5. There needs to be a stronger push for user retention solutions.

Ever bought a FitBit or other activity monitor? Singh is willing to bet that if you have, it saw religious use for a few weeks before being tossed in a drawer. With wearable technology, he said—no matter how popular the device—user retention tends to be low.

“User retention is a big problem when we try to connect lives with devices,” he said. “We have to create a value-based care model, but we have to provide incentivization for both the provider and the patient to use this information in making sure they’re providing the best care.”

More affordable payment models could help, he said, as well as further deep learning for actionable intelligence.

“That’s going to require some major training and behavioral economics in certain trials and studies to make sure that these changes can be implemented and reproducible and last,” he said.

 

Source: http://www.cardiovascularbusiness.com/topics/electrophysiology-arrhythmia/innovations-heart-tech-5-things-standing-between-now-and-better-medical-technology

Russo Partners Teams with Medovex to Highlight Medical Technology Innovation with DenerveX System by Drue De Angelis

NEW YORK, Nov. 13, 2017 /PRNewswire/ — Russo Partners LLC and Medovex Corp. (NASDAQ: MDVX) have teamed to call attention to the need for new treatments for chronic back pain and the Company’s innovative solution known as the DenerveX®…

NEW YORK, Nov. 13, 2017 /PRNewswire/ — Russo Partners LLC and Medovex Corp. (NASDAQ: MDVX) have teamed to call attention to the need for new treatments for chronic back pain and the Company’s innovative solution known as the DenerveX® System. Currently approved for use outside of the U.S., DenerveX is a new device designed to enable doctors to provide patients with enduring relief of back pain caused by Facet Joint Syndrome.

The Medovex public relations initiatives include an extensive video campaign featuring spine surgeons worldwide. Wilcots, an NFL broadcaster, former professional football player and leader of Russo Partners’ Sports-Health Alliance, recently interviewed doctors at the EUROSPINE 2017 annual meeting in Dublin and the North American Spine Society (NASS) conference in Orlando, where he also taped a demonstration of the DenerveX System in use in a surgical cadaver lab. Russo Partners and Medovex will integrate the content into ongoing social and traditional media initiatives this quarter as Medovex continues its country-by-country roll-out of the medical technology.

“Solomon has the natural ability to bring professionals together and craft medical stories in a natural and impactful manner,” said Patrick Kullmann, president and COO of Medovex. “We look forward to using the output of his work to increase the visibility and awareness of what we are doing at Medovex to transform how surgeons and pain management physicians treat a common source of chronic back pain. This is a meaningful change with our DenerveX system that is focused on long-term relief.”

Wilcots added, “Chronic back pain, including that caused by Facet Joint Syndrome, is common among former professional athletes. The opportunity presented by the DenerveX System is one of giving people back quality of life without reliance on prescriptive pain relief medicines. This is exciting technology about which physicians were eager to speak with me and share their perspectives on how it will change their practices and patients’ lives. We will continue with these initiatives throughout 2018.”

The DenerveX System is a non-addictive opioid drug alternative capable of restoring a patient to a more normal and active lifestyle. It was designed by medical professionals for medical professionals to enhance a patient’s quality of life. Using highly differentiated technology, the DenerveX System denervates and removes capsular tissue from the facet joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and radio frequency ablation treatment on the facet joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint. To learn more about the DenerveX System, visit http://medovex.com/us/denervex-system/.

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in countries worldwide, including the U.S. and countries in the EU. This condition affects millions of people each year, and current treatment options are generally temporary with no proven long-lasting option.

About Medovex

Medovex Corp. was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with Facet Joint Syndrome at significantly less cost over time than currently available options. To learn more about Medovex, visit www.medovex.com.

About Russo Partners’ Sports-Health Alliance

The Sports-Health Alliance is an award-winning public relations service at the intersection of health, medicine and sports. Launched by Russo Partners in 2017, this offering leverages the agency’s inside access to athletes, broadcasters and sports business leaders who have a shared passion with their clients for a disease or treatment. The Alliance was cultivated over a two-year span and involves Russo Partners’ Team Leader Solomon Wilcots. Visit https://russopartnersllc.com/services/sports-health-alliance/ for more information.

About Russo Partners

Since 1988, Russo Partners, formerly Noonan/Russo Communications, has provided public and investor relations and corporate communications services to both emerging and established healthcare and technology-centric companies worldwide. The agency’s staff is comprised of senior executives with extensive backgrounds in science, medicine, finance and communications. Visit www.russopartnersllc.com for more information.

 

Source: http://www.orthospinenews.com/2017/11/14/russo-partners-teams-with-medovex-to-highlight-medical-technology-innovation-with-denervex-system/

Can Technology Mend America’s Divided Healthcare System? by Alison E. Berman

40 million people in the US lack the security of having a guaranteed meal each day. The US also wastes $40 billion dollars of food each year. It’s a harsh contrast.It seems, however, that it’s a condition we’ve come to accept.“It’s acceptable for so…

40 million people in the US lack the security of having a guaranteed meal each day. The US also wastes $40 billion dollars of food each year. It’s a harsh contrast.

It seems, however, that it’s a condition we’ve come to accept.

“It’s acceptable for some people to work 40 hours a week at a minimum wage that keeps them below the poverty level,” Dr. Gloria Wilder said to the audience at Singularity University’s Exponential Medicine. Wilder is a street doctor, CEO of Core Health, and VP of innovation and preventive health at Centene Corporation.

Poverty isn’t the only such condition the US tolerates. We’ve also accepted a healthcare system divided by social class.

“We have economic segregation in health care, and we have for a long time,” Wilder says. “Depending on what card is in your pocket, you can determine what you can buy in the healthcare system… 80 percent of the impact of health has to do with where you live, how you live, and the environment you grow up in.”

 

On stage with Wilder was Josh Lee, principle at Deloitte Monitor and specialist in healthcare strategy. Lee said the US spends $10,000 per capita on health care, which is more than the 11 other wealthiest nations in the world. Yet we have the lowest life expectancy and quality of care.

“We are getting a very low ROI,” Lee says. “We’re spending 30 percent more than the rest of the OECD (The Organization for Economic Co-operation and Development)…and we’re spending 30 percent less than our peers on social support and public health.”

Class Shouldn’t Determine Care

Disparity in medical treatment is embedded in America’s healthcare system. It’s a painful truth, and the consequences of limited access to quality doctors and health insurance often creates devastatingly different health outcomes for patients with different income levels.

“On one side of the city, there are seven academic institutions and hospitals. On the other side of the city, there’s one. 47 percent of the children live on the side of the city where there’s one hospital. It had, in the past, no pediatrics at that hospital. As a pediatrician, I used to tell mothers whose kids were having an asthma attack to call a cab. I’d say, ‘Don’t call an ambulance. When the cab gets you halfway across the bridge to the other side of the city, call the ambulance, because then the baby will be taken to a pediatric hospital and will live.’”

Gloria Wilder, MD, MPH, CEO at Core Health and VP of Innovation and Preventive Health at Centene Corporation (center), Lee M. Sanders, MD, MPH and Associate Professor of Pediatrics at Stanford (right), and Josh Lee Principal at Deloitte Monitor (left) at Exponential Medicine.

Wilder wrapped up her portion of the talk and handed the microphone to Lee Sanders, associate professor of pediatrics at Stanford University, who posed the question he wrestles with daily: “How do we create a care system that meets everyone’s health needs?”

Sanders outlined three primary barriers to health equity that determine outcomes: chronic care coordination, preventative care, and health literacy. His model examines these barriers and assesses the risks they pose to the most disadvantaged population groups.

“For every condition, there’s efficacy treatment or prevention, and efficacy technology. Our job is to create access to that technology for everybody who needs it,” said Sanders. Efficacy technology can range from vaccines to chemotherapy to nutrition for a pregnant woman.

Social factors determine more than 50 percent of health outcomes, and knowing this, Sanders urged the audience to think about health technology within the social context of treatment. Specifically, it’s critical to view the relationship between social and biological factors as intertwined rather than opposed, and to make technology solutions that mirror this elastic association. 

“In the US, one in four children live in poverty. We have technology that can help each and every one of those children,” said Sanders. “We have immunizations, and screening, and early nutrition programs, and early developmental programs, but fewer than 50 percent of those children are getting that technology that we know works.”

It appears technology solutions alone cannot solve our nation’s health problems if they are not created to function within the social context of a patient’s real life. New health technology must be paired with effective systems focused on creating timely access and distribution of services. 

Our Shared Challenge to Tackle

Wilder, Lee, and Sanders all shared a common goal and challenge for the room.

They want to see entrepreneurs and people beyond the scope of medical practitioners start harnessing the power of innovation to disrupt the social determinants of health. In doing so, they hope to create better and more equal health care outcomes in the country.

“This is going to require creative energies from the people in this room,” says Sanders. “Not more pediatricians or social scientists, but you, entrepreneurs, thinkers, people who are developing the technologies of the future to make sure that we marry high tech with high touch to get services to the people that need them.”

Though there are examples of innovative health programs that are making a positive impact, it seems like many remain siloed. UberHEALTH, for example, could offer on-demand care, but this is likely a service that only the wealthy could afford.

An example on the other end of the spectrum is the HAIR Campaign program in Maryland. It’s an incredible community-based intervention program to make barbershops and beauty salons spaces where the community can access health education and medical services. But this program seems to lack a technical component.

There’s a long road ahead for blending public health work and health technology, but the outcome could be powerful.

 

Source: https://singularityhub.com/2017/11/08/can-technology-mend-americas-segregated-healthcare-system/

Therapeutic Goods Administration rejects claims it is 'too close' to medical industry by Melissa Davey

Australia’s drugs and medical devices watchdog has denied it is too close to the industry or that receiving funding from health and medical companies is a conflict of interest, after its independence was questioned by health experts.On Monday Dr Wen…

Australia’s drugs and medical devices watchdog has denied it is too close to the industry or that receiving funding from health and medical companies is a conflict of interest, after its independence was questioned by health experts.

On Monday Dr Wendy Bonython from the University of Canberra’s Health Research Institute told Fairfax Media that the Therapeutic Goods Administration’s [TGA’s] industry funded model of regulation needed a complete overhaul,including “a clear break between the regulator and the parties they’re trying to regulate”.

Bonython said accepting fees from industry was unacceptable in the wake of the transvaginal mesh scandal that saw the TGA approve meshes for use in treating prolapse despite a lack of evidence for the safety and efficacy of the products. Thousands of women who received the meshes have reported complications including severe pain and damage to nerves and nearby organs, including the bladder and bowel.

On Tuesday Ken Harvey, a professor of public health and preventive medicine at Monash University, criticised a decision by the TGA to allow a supplement company to promote a herbal remedy as helpful in relieving the symptoms associated with an enlarged prostate, despite scientific evidence to the contrary. Harvey told Guardian Australia it was “another example of them [the TGA] being very helpful to industry while being ineffective from a consumer protection point of view”.

The criticisms prompted the TGA to release a statement on Wednesday saying it “totally rejects claims” of a “too close relationship between regulator and industry because of this funding model”.

“While fees received, for example, for the evaluation of a product are used to fund staff time on evaluation of that product, they are not refunded if the application is rejected or withdrawn,” the statement said.

“Industry has no say whatsoever in how TGA spends the revenue it receives from other industry charges. This system has been in place for more than 20 years and there has been no evidence of any sort of regulatory capture.”

In regards to transvaginal meshes, the TGA said it could only make decisions based on evidence available at the time. In 2008 an expert committee found the reported rate of complications from the meshes was low, with complications closely linked to the skill and training of the surgeon and the patient selection.

“So at that time it would have been inappropriate to implement some of the measures that have been introduced more recently,” the TGA said.

In October last year the TGA announced it was reclassifying transvaginal meshes as “high risk” following post-market reviews conducted in 2010 and 2013, and that this new classification and additional regulations around the devices would commence in December next year with a staged transition period. From July 2012 to 1 June 2016, the TGA received 99 adverse events reports involving urogynaecological surgical meshes, with pain and erosion the most frequent complaints. The TGA acknowledged adverse events were likely underreported.

“Other medicines and device regulators internationally also are fully or significantly funded by industry fees and charges and operate in the same way,” the TGA statement said. “This takes the burden off the taxpayer for such time-consuming scrutiny."

But, in a complaint to the TGA, Harvey accused the regulator of being “disingenuous”.

“Regardless of whether the regulator is funded by industry fees or the government, the consumer pays, either through higher prices on therapeutic goods or increased taxation,” he said.

“Second, how many other therapeutic goods regulators are 100% funded by industry? The benefits of industry funding are that the regulator is not constrained by cutbacks in government budgets, efficiency dividends and other constraints. The downside is that industry has a greater say in how its fees are used and there is an increased risk of regulatory capture.”

 

Source: https://www.theguardian.com/australia-news/2017/nov/08/therapeutic-goods-administration-rejects-claims-it-is-too-close-to-medical-industry

Life Saving Medical Technology Brings Emergency Hospital Care to You by Sandy N. Vyjay

As the world has unfortunately witnessed over the last few months, hurricanes are both a prevalent and catastrophic disaster. Between Hurricane Harvey in Texas, Hurricane Irma in Florida and the U.S.Virgin islands, and Hurricane Maria in Puerto Rico…

As the world has unfortunately witnessed over the last few months, hurricanes are both a prevalent and catastrophic disaster. Between Hurricane Harvey in Texas, Hurricane Irma in Florida and the U.S.Virgin islands, and Hurricane Maria in Puerto Rico, total death tolls amounted to over 260. In situations like these, relief efforts that are successfully executed in a timely manner tend to be few and far between. This is why, more than ever, innovative technology for emergency care is necessary, no matter where in the world it may be or when it may occur.

Disasters, whether they be earthquakes, hurricanes, or ongoing violent conflicts are often unpredictable and complex. No matter how much a population goes into preparing for one, the need for prompt emergency medical attention is continuous, while resources are often limited. This is why innovative technologies for emergency medicine and trauma care are considered to be the most efficient, and therefore the most vital. The Israel Pavilion is known to bring the most profound of these technologies, focusing on clear and concise needs for first responders in emergency situations. They will be presenting EMS with specialized products conceived by teams of R&D engineers and accomplished executives, that are supported by internationally renowned medical experts specific to intensive care,respiratory, cardiac, central nervous system and trauma medical emergencies.

MEDICA 2017, a trade fair for the world’s key players of the medical industry, seems to be coming in at one of the most crucial and relevant times. One of those key players? The Israel Export and International Cooperation Institute (IEICI). IEICI is a non-profit organization that promotes Israeli trade relations, cooperation, and strategic alliances with overseas companies. They will be presenting Israel’s leading Medical Device and HealthCare IT leaders in the MedTech field at the Israel Pavilion at MEDICA 2017. Together with Israel’s Foreign Trade Administration at the Ministry of Economy and Industry, the Israel Pavilion is introducing advanced emergency medical and digital health solutions tailored for every patient and every type of care in emerging medical technologies.

It is important to note that these medical devices are not limited to only Israel, but rather are introduced to connect the international community with Israel’s innovative medical technology for impact on a global scale. Major strides are being made towards critical respiratory and cardiac aid, digital monitoring, and blood and fluid control.

Respiratory and Cardiac Aid

One of the most imperative types of care in emergency situations is focused on making sure the patient can breathe. Unfortunately, it may be too late by the time that first responders are able to transfer the person to a hospital. So, what if hospital services could come to you? Inovytec

Inovytec Medical Solution, combines multi-functionality and light-weight portability for out-of-hospital, first-responder critical conditions. They offer a first-line solution specifically for respiratory and cardiac critical aid with three non-invasive technologies for treatment: The Lubo, The SALI, and The VentWay. All are designed for out-of-hospital critical care and oxygen therapy in field conditions and during transit. Guide in Medical is a medical device company specializing in the respiratory field enabling clear tracheal identification as well as fast, accurate and safe intubations. Guide in Medical’s intubation device is a non-invasive electronic illumination patch that can be placed on the patient’s neck. Once activated the device transmits the signal to the underlying tissues, where the signal is completely absorbed by the surrounding tissues and a fraction is emitted solely by the trachea enabling clear identification of its location during intubation procedures. The unique device is meant for one-time-use, is disposable, and most importantly, facilitates intubation in the most difficult clinical situations. Another company centered around personalized and portable medical care is CardiacX Medical Ltd. They develop, manufacture and market cardiac resuscitation solutions, including the world’s first miniature personal external defibrillator (PED). Similar to the size of a smartphone, PED is able to deliver the same energy and number of biphasic pulses comparable to the public AED. Imagine having something with that much impact, in that small of a size. The PED will raise the out-of-hospital survival rate from 5% up to the in-hospital survival rate of 50% or more. Each device stays with the patient all the time, making the survival rate independent of the victim’s location. And let’s face it… if people can stay connected to their smartphones, they can stay connected to their PED.

Subscribe to The Morning Email.

Wake up to the day's most important news.

 

 

Digital Monitoring

It can become confusing, stressful, and disorganized to monitor multiple things at once in a critical situation, which in itself fosters an environment for human error. Better to have a device do it for you. Medisim Ltd is one of the leading and innovative forces in developing non-invasive professional and home thermometry products. Its Temple Touch Pro system provides core temperature monitoring and management that is fully operational during patient alertness or anesthesia. Based on unique conductive heat flux technology, Temple Touch Pro offers a premium yet cost-effective temperature monitoring solution for clinical and at-home environments. Flight Medical, developed state of the art ventilators, now operating in 50 countries, that provides ICU quality affordable ventilation with its double battery concept Flight 60. There is a growing need for ventilation spanning across many situations, and Flight 60 is a cost-effective, compact and lightweight ventilator offering advanced monitoring, easy use, and invasive and non-invasive capabilities. In 2017 Cnoga Medical Ltd. raised $50 million dollars to help further establish and distribute its non-invasive medical monitor devices. Portable and easy to use, patients simply place their finger in the CNOGA device and, with a unique algorithm, the automatic measurement provides the 14 blood parameters in under 60 seconds for non-invasive, needle-free glucose monitoring. CNOGA offers, TensorTip glucometer for diabetics, VSM for blood pressure monitoring, and MTX for noninvasive blood hemodynamics and blood chemistry analysis.

Blood and Fluid Control

In emergency situations, you can expect to see a lot of blood that can prove difficult to control. Core Scientific Creations Ltd. is the wound management and emergency medicine services behind WoundClot. Uniquely engineered to control non-compressional mild, moderate and severe bleeding, Wound Clot is the only bio-absorbable hemostat approved for severe arterial bleeding. Whether it be vascular, soft tissue, bones, or severe traumatic hemorrhage, WoundClot stops all types of bleeding through a biological clot, that is fully absorbed by the body within seven days. QinFlow Ltd. (short for Quality in Flow) has worked since 2008 to develop and perfect an extremely efficient fluid warming technology. The company’s flagship product – the Warrior – provides front-end rescue teams, paramedics, critical care transport teams, ER teams, trauma centers, intensive care units and operating rooms with a reliable, simple to operate, and completely portable blood and IV fluid warming device that operates flawlessly in all environmental conditions in order to fight hypothermia and save lives.

The theme across all of these innovative technologies is portability and durability, making it accessible and easy-to-transport in any and all situations. No longer will you need to wait for the dust to settle (no pun intended) to receive hospital level critical care. Now, it can come to you.

 

Source: https://www.huffingtonpost.com/entry/life-saving-medical-technology-brings-emergency-hospital_us_5a03e193e4b0204d0c17146d

Where is the future of medical technology heading? by Brian Wyatt

Medical innovation has undergone significant transformation lately, driven by personal and portable devices and the ability to integrate them with personal healthcare and information technology systems. This year, we have witnessed tremendous growth…

Medical innovation has undergone significant transformation lately, driven by personal and portable devices and the ability to integrate them with personal healthcare and information technology systems. This year, we have witnessed tremendous growth in the increased integration of Internet of Things (IoT), wearables and other diagnostics as well as growing integration of information technology, connectivity, access and personalised medicine. In addition, the industry is learning from other sectors about the use of innovative technology platforms and how they streamline processes.

In both established and growing economies, healthcare product evolution and innovation are focused on addressing three problems: ageing populations, high patient volume and the need to build cost effective healthcare. These macro trends have increased demand for more cost-effective solutions and engagement from consumers in healthcare initiatives. In this article we will explore how portable healthcare, big data and the better integration of services will deliver preventative care and population health, as well as build efficiencies and cost savings for success.

Healthcare gets a portable makeover

Patients are becoming more empowered to monitor and improve their well-being through personal and wearable devices. They also want better and cost-effective healthcare solutions, so the use of tablets and smartphones for health monitoring purposes continues to increase. At the 2017 Consumer Electronics Show (CES), Samsung launched a smart belt that tracks a key health predictor: a person’s waist circumference to track changes in waist size over time and make the user more aware of bad eating habits or even minor waist gains.

We are also seeing growth in remote and virtual monitoring devices owned by healthcare organisations that patients take home for a period of time. These are transforming the way healthcare professionals provide efficient patient care.

The overall medical device market is expected to reach $343 billion by 2021 and is forecast to grow at a CAGR of 4.6% between 2016 and 2021, according to Research and Markets. The medical device connectivity market is maturing too, and is expected to grow at a CAGR of 38% until 2020. An ageing population, demand for personalised treatment, and increased availability of healthcare are the major drivers behind this growth. In accordance with this trend, the remote and virtual healthcare industries are anticipated to benefit from this growth.

A growing segment of monitoring devices are available for collecting and tracking data related to general vital signs (heart rate, blood pressure and temperature) or other metrics, such as electrocardiograms (ECG) for those with heart issues or blood sugar for diabetics. For instance, Boston Scientific made breakthroughs in a trial last year for an implant that predicts heart failure a month before it happens and has recently confirmed that new data confirms the HeartLogic Diagnostic enhanced the ability to classify patients at high or low-risk of experiencing a future HF event.

Some of these products not only provide diagnostic monitoring but also apply physical therapy or adjust ongoing therapy of implantable devices. Using Bluetooth and similar technology, caregivers can also track movements of elderly and vulnerable patients. The data is then transmitted to health professionals in facilities to monitor these patients remotely and act on the information received as part of the treatment plan. Soon there could be less of a need for someone to visit the physician’s office.

Combining healthcare data with new solutions

Interoperability solutions for exchanging patient data across care settings is another technological development shaping healthcare organisations and the way clinicians interact with patients. By including post-acute care in interoperability strategies, healthcare organisations can ensure that critical patient information across all care settings will be connected, providing a more detailed patient picture for more specific treatment plans and improved patient care.

Extending connected solutions to patients who live in remote or rural areas or have transportation issues and would otherwise be challenged to return to the point of care, the physician’s office or hospital is a true game-changer for the industry.

Research has found that between 25 to 50 percent of referring providers are not aware of whether their patients have completed their referrals, while approximately 50 percent of referring and specialist providers do not communicate with each other. The cost of this referral leakage can be reduced by a proper referral network management program that database and consulting companies can help monitor. Hospitals are reportedly starting to make changes in their budgets to identify programs that can help patients receive better care, and save their staff’s time in the process.

Beyond large hospital systems, small-to-mid sized practices also struggle with different workflow requirements with suppliers and other providers that do not necessarily interact.  Without an ability to exchange information digitally, the process breaks down, time is wasted, and there are risks that information becomes inaccurate. This may also give patients more flexibility to change if their preferred provider is in a different network.

Traditional healthcare companies generally have been reluctant to adopt some of the fast-moving technology changes, instead choosing to wait for regulatory agency guidance given to these new products and uses along with marketplace acceptance. This has allowed entrepreneurs with smaller companies to open innovation to stakeholders within healthcare.

Blending innovation across industries

There is potential for medical device and imaging markets to leverage new technology platforms to reduce development time, save investment costs and lower barriers to market entry. Medical technology design must rely on distinguishing features and market adoptability to ensure it is in-line with global megatrends, with many innovations carrying forth a technology convergence that is prepped for a "smart" world.

This trend is creating an openness to innovation in a highly regulated industry, allowing new technologies and products to be developed by companies outside of the healthcare industry. The likes of Google and IBM, for instance, are investing in technologies and building partnerships to be a part of this growth. Google’s DeepMind now works with the NHS in the UK to provide mobile tools and AI research to get patients “from test to treatment” faster and as accurately as possible.

We are in an age where knowledge spill overs and blending innovation between sectors will become more frequent. Consequently, manufacturers may launch technologies in less-regulated markets in the developing world, where more innovation originates and laws governing the use of such devices isn’t as strict.

Manufacturers will need to be flexible and adopt a new approach to global medical device demand. The way people are responding to and adopting an interconnected way of living gives clues about how they want to approach healthcare. Even so, clear differences between end users, local regulators and quality challenges must be factored into plans for investment and entrance into different markets.

Source: https://www.medicalplasticsnews.com/news/opinion/where-is-the-future-of-medical-technology-heading/

How The Rise Of Medical Technology Is Worsening Death by Jessica Nutik Zitter

Our aging population is at risk from a most benign-appearing source—the medical technologies we trust to keep us healthy.When they were first widely used in the 1930s and 1940s, breathing machines did what humans could never have imagined a generati…

Our aging population is at risk from a most benign-appearing source—the medical technologies we trust to keep us healthy.

When they were first widely used in the 1930s and 1940s, breathing machines did what humans could never have imagined a generation earlier: They kept young polio victims alive until their bodies cleared the virus that had temporarily weakened their respiratory system. Thanks to these miraculous machines, tens of thousands of these patients recovered and went home to live out the rest of their lives. This bold new use of medical technology riveted the world and set the stage for a new era in medicine, in which an overriding faith in the curative powers of technology prevailed. Over the next several decades, doctors assumed that everyone wanted and deserved access to these treatments. The breathing machine, or mechanical ventilator, was the first of many life-prolonging technologies to come. Now, there are machines to substitute for a wide range of physiological functions, including the pumping of the heart and the oxygenation of the blood.

Ideally, life-support technology should serve as a bridge to recovery, in which the failing organ is supported until the underlying disorder improves. But when the underlying disease or failing organ will not recover adequately to resume independent living, the recipient is likely to remain dependent on the machine. Unlike the polio victims, whose young and otherwise healthy bodies were often able to spring back to life after their illness had passed, the frail elderly and terminally ill are much less likely to recover. And so they are attached surgically to machines, most commonly through a tracheostomy tube in the neck and a feeding tube in the stomach. These patients cannot live at home and must remain in facilities where they are cared for by trained personnel. Most will never get out of bed again, eat independently, or talk. Many will lie in hospital beds, their arms tied down to prevent dislodgment of tubes, until they die.

According to the Department of Health and Human Services, over the next 45 years, the population of people older than age 65 will double. From 46.2 million in 2014, the number will climb to 98.0 million in 2060. In 2030, one out of every five Americans will be older than age 65. If trends continue on the current path, this will translate into millions of elderly patients on life support.

The SUPPORT Trial of 1996 was the first wake-up call to the medical community on the state of dying in America. It reported astonishing rates of mechanized deaths, accompanied by significant patient pain and suffering. Often, patients or their families had little or no prior communication with physicians about decisions to use these treatments. The mechanical ventilator, cardiopulmonary resuscitation, and dialysis machines are familiar mainstays of intensive care, and unless patients opt out, they drive the treatment plan. Doctors reach for them. And most patients, educated on these topics by inaccurate media portrayals, expect them. Substantive conversations about prognosis and treatment plans rarely take place, and patients’ understanding of their condition and treatment options are poor. But despite subsequent efforts by the palliative care community and others to reverse this situation, in 2013, the Journal of the American Medical Association reported an increase in intensive care unit (ICU) stays for patients older than age 65 in their last month of life.

Today, there is a steadily expanding menu of technological treatments designed to support a multitude of failing organs. An example is extracorporeal membrane oxygenation (ECMO), a form of cardiopulmonary bypass (CPB). CPB was developed in the mid-twentieth century for use during heart surgery. Like hemodialysis, which compensates for failing kidneys, CPB can take over for hearts while under the surgeon’s knife. The blood circulates through the machine, transported in and out of the body through large cannulae. The CPB machine oxygenates the moving blood and then pushes it back into the body, maintaining pressure and circulation. ECMO is conceptually and mechanically similar but is intended for longer-term support in patients who will remain, for days, weeks, even months, in the ICU. It was initially conceived in the 1940s but was largely relegated to research purposes and then to the treatment of neonates. However, during the swine flu pandemic of 2009, survival rates for adults receiving ECMO for respiratory failure were found to be higher than seen in earlier studies of the technology. Following that, there was a substantial rise in the number of ECMO centers worldwide, going from 148 in 2008 to 298 in 2015.

The ECMO machine can serve to support diseased lungs, or hearts, or both. Large catheters bring poorly oxygenated blood from the body to the machine, where it is oxygenated and then sent back to feed the tissues of the body. The goal is to support the body until the lungs and/or heart recover, or are transplanted. In the meantime, the patient can live in the ICU on this machine. While some patients are able to move around in the ICU, with staff carefully carrying the machine and catheters behind them, others lie in beds, either too weak to move or dependent on the breathing machine.

Intended as a bridge to recovery or a bridge to transplant, for some, this technology becomes what is called a bridge to nowhere. If a patient’s organ will not recover and the patient is not a candidate for transplantation, the remaining options are bleak. Such patients will likely suffer many complications aside from their underlying condition, including increased risk of bleeding, profound fatigue, cognitive decline, deconditioning, and serious infections with drug-resistant organisms. But arguably more difficult is the decision they face about how to proceed. Unlike patients on breathing machines, these patients are often awake and able to communicate. And so they must answer an important question. Are they willing to live the rest of their life in an ICU? If not, when to disconnect the machine? Most, once disconnected, will die within a very short period of time. How do doctors ask patients, many of whom didn’t elect for this treatment but were placed on it while in extremis, to decide what day they want to die? And one cannot ignore the issue of resource allocation. If a person does not wish to end his or her life, he or she may be using a precious and scarce resource that could save another patient.

With its rapid explosion in use and new centers popping up around the country and the world, there are voices advising caution. Doctors Daniel Brody and Ken Prager of Columbia Presbyterian, both ICU doctors who manage ECMO patients at their established and experienced center, have concerns about this rapid increase in its use. Their protocols for inclusion are very strict, and they will only accept patients for ECMO who are candidates for transplant, have physiologic reserve and good nutritional status, and have a high likelihood of robust recovery. Their intensive screening of candidates has paid off, and most of their patients do well. But if this technology begins to be used without careful screening, it is likely to create a situation similar to the overuse of the ventilator, where benefits are outweighed by great burden.

ECMO is only one of many emerging technologies or treatments becoming available to the modern physician. While these technologies can be truly miraculous for the right patients, others—specifically, the frail elderly, terminally ill, and the dying—will not be so lucky. As the US population ages, the current epidemic of overly mechanized deaths threatens to explode into a major public health, and fiscal, crisis. For ECMO alone, there was a 433 percent rise in its use in adults between 2006 and 2011. And for each patient, the mean estimated total hospital costs, including pre- and post-ECMO procedures, was $213,246. The projected costs are staggering.

When surveyed about medical preferences at the end of life, most people do not choose this course of treatment. And for patients already in the ICU, data demonstrate that the more information patients are provided about their prognosis and treatment options, the less technology they choose. And so this high use of technology that has become the default course of medical culture does not appear to match the needs of patients.

In the mid-twentieth century, French anthropologist and energy minister Jacques Soustelle noted with concern the powerful draw of humans to new technologies such as the atom bomb. He determined that “since it was possible, it was necessary” and imagined an arms race that might ultimately destroy us all. Many others have warned of a “technological imperative,” in which the mere existence of increasingly sophisticated technical capabilities rendered their use necessary, even inevitable. When it comes to the dying, this tendency can take a substantial toll at a vulnerable time.

Medical technology can indeed be miraculous. It has saved countless lives that in previous times would have been lost. But there can be substantial costs, both human and financial. Many patients die protracted deaths on mechanical ventilators—deaths which, based on data about preferences, many would not have chosen had there been adequate communication. Even a treatment with a powerful record and clear physiologic indication might, in some, cause profound suffering.

Patients need to understand that potential at the outset of their treatment and remain in clear communication with their physicians as their trajectories unfold. Physicians, as stewards of these technologies, have a responsibility to direct the use of these technologies toward patients who are most likely to benefit, instead of viewing these treatments as a default for all patients. And once they have attached their patients to these technologies, physicians must engage in ongoing dialog with the patient or family to ensure that the medical plan remains in alignment with the patient’s preferences, which may change as the prognosis becomes clearer. As new life-support technologies such as ECMO are used more widely, more patients will be left stranded on the “bridge to nowhere.” As a society, we must look carefully at our US tendency to celebrate technology and to assume that “doing something” implies that we care.

 

Source: http://www.healthaffairs.org/do/10.1377/hblog20171101.612681/full/

How Tech is Changing How Businesses Raise Money by Sue Marquette Poremba

In the not-so-distant past, if an individual wanted to raise money to start or grow a business, it required either loans from a financial institution, personal wealth or backing from family and friends. It was a very inefficient way to raise capital…

In the not-so-distant past, if an individual wanted to raise money to start or grow a business, it required either loans from a financial institution, personal wealth or backing from family and friends. It was a very inefficient way to raise capital. It also limited budding entrepreneurs to a small circle of personal contacts.

Technology has changed how small businesses raise capital. It has opened doors for talented entrepreneurs who otherwise wouldn't have had access to funding and created a level playing field for people of all backgrounds.

"The main advantage is that you can expand your reach beyond your direct network and geographical region,” said Joel Keylor, co-founder and CEO of Tresle, a platform that connects established private companies with verified buyers and capital.

"It also makes it far quicker. You can leverage a bigger audience. Fees, if applicable, are upfront and clear."

Use technology to generate leads

Ben Larson of Gateway, an investor and startup mentor, recommended leveraging Angel List, Crunchbase, LinkedIn and any other network or database you can to understand what types of investments investors are making, whether they're competitive or complimentary, and to learn the typical check amount and their investment thesis. And, most importantly, you should use these sites to see how you are connected, either directly or through channels, to find out who will make good contacts and who could introduce you to good contacts. [Read related article: Crowdfunding for Startups: 10 Kickstarter Alternatives]

"We encourage the startups that we work with to treat fundraising like they would a sales pipeline,” said Larson. "A successful raise requires lead sourcing, refining sales communications and materials, and optimizing each stage. As with every sales funnel, it all begins with leads. They should be well targeted, copious, and come with a warm introduction when possible."

When you make those initial contacts, the first step is to organize an efficient fundraising process in a CRM or sales software like Pipedrive, Larson suggested. This will force you to understand each step of your sales process, how long it takes you to move from one stage to the next, and it gives you a visual representation of the health of your pipeline.

Crowdfunding your business

Entrepreneurs and small business owners have turned to crowdfunding for more than a decade, raising billions of dollars for business investments since 2009.

"Instead of shopping a business plan to several different banks and financial institutions, crowdfunding platforms let an entrepreneur showcase his or her idea and provide investors of all sizes an opportunity to participate in growing the business," wrote Sheila Olson in an article for Investopedia.

Popular platforms for business-related crowdsourcing include Kickstarter and Indiegogo. Some platforms will let you keep all of the monies raised even if you don't make your goal; others will not allow you to collect any money if goals aren't reached.

In some cases, you will be asked to provide an incentive upfront – donors receive a prototype of the product or get a percentage of the profits. Even with the risks and the profit-sharing, many turn to crowdfunding sites because they reach people on a global level, thanks to social media and other internet marketing avenues.

Cryptocurrency and blockchain

Startups and entrepreneurs are more frequently turning to blockchain technologies for an initial coin offering (ICO) and as a way to raise money without having to give away equity to donors.

"Blockchain software provides a ledger for recording and verifying transactions and other information among multiple parties without expensive intermediaries like brokers or exchanges," Tomio Geron wrote in the Wall Street Journal

Cryptocurrency is a form of blockchain technology, which is really just a trusted ledger of transactions, explained Micah Tapman, managing director of Canopy, a cannabis industry investment fund. Previously this was the purview of third parties, banks and governments. Now any company can create this trusted ledger and use coins internally.

"The benefit to a company is that these coins (also referred to as tokens) are mathematically verified using the blockchain technology so you're not reliant on the memory/record keeping of the company to the same degree you would be with an old-fashioned credit account," Tapman said. "So, given that scenario, a company-created cryptocurrency is valuable if the company has a way for you to spend the money. Otherwise, the coin has no inherent use."

Technology hasn't solved all of the problems of raising capital for new business ventures or product ideas. You still have to find good, honest people to support you, and you still have to do plenty of legwork to make yourself stand out in an ocean of other new startups and ideas.

Yet, said Keylor, it turns out that technology can be a great way to make new relationships and find the right backers who can help you grow your business.

 

Source: http://www.businessnewsdaily.com/10341-technology-changing-how-business-raise-money.html

How smarter health technology is improving our quality of care by Chris Price

first.JPG

There’s no doubt that increasing costs, coupled with an ageing population, are putting unprecedented pressure on health care systems across the world.

According to Frost & Sullivan’s Social Innovation in Healthcare report, the number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050; meanwhile total health and long term care is set to double to nearly 14pc of GDP among OECD countries. Among the BRIC countries, which are starting from a much lower base of around 2.5pc, that figure is expected to rise to around 10pc of GDP.

There’s a lot that can be done as we move towards new technologies, which will improve the health status of patientsAdrian Conduit, director, Hitachi Consulting

Furthermore, a Deloitte Centre for Health Solutions report claims that in the UK the health care funding gap is set to reach £30 billion for 2020-2021, with the rise in chronic health conditions expected to cost £5 billion a year by 2018.

“The global healthcare market faces the dual challenge of ageing population and chronic diseases,” explains Adrian Conduit, director at Hitachi Consulting. “There’s a lot that can be done as we move towards new technologies to manage and self-manage chronic conditions, which will improve the health status of patients.”

 

Personal tools

One solution lies in the implementation of new smart health technology. Already there are 165,000 health related apps on the Apple app store, with the market showing a 30pc year-on-year increase.

Frost & Sullivan predicts that next generation wearable devices and healthcare-centric apps have the potential to reach $25 billion globally by 2020 with a much higher percentage of apps set to include clinical grade functions.

For example, technologies such as wearable devices, sensors and other patient monitoring devices (PMDs) can help those with Alzheimer’s to continue living at home for much longer. Sensors can be placed around the home as well as in appliances and on the patient’s body, with caregivers able to track and monitor movements through smartphone apps. Alerts are then received if meals are missed, they do not get out of bed, if they fall, or if there are any other signs of risky behaviour.

Similarly, many NHS trusts are starting to introduce PMDs for patients with long-term chronic illnesses to monitor changes in their condition remotely and adjust medication accordingly.

But smarter health isn’t just about devices and apps. While data is currently extremely fragmented across facilities and regions, the use of big data analytics from large patient groups is increasingly being used to discover mutations and markers in order to provide valuable insight for drug development and improve patient outcomes.

According to Frost & Sullivan, the healthcare sector is set to generate between $350-400 billion worth of valuable data by 2020, ranging from simple lab-test results to full clinical trial studies.

second.JPG

 

Tailored solutions

Hitachi is one company at the forefront of this connected health revolution, with its healthcare IT and medical technology solutionssupporting the various needs of the health care cycle from prevention and check-up to screening and treatment.

A great example is at the Klinikum Wels-Grieskirchen hospital in Austria, where Hitachi Data Systems (now Hitachi Vantara) has established a private cloud that is unique in Europe. Data is stored in a multi-tier storage solution based on Hitachi Unified Storage VM (HUS VM), enabling users to access the right information at the right time, in the right place and in the right format.

Hitachi Clinical Repository has the flexibility to integrate any type of clinical system into a comprehensive archive, so users can search for data across all systems, regardless of manufacturer or location.

Furthermore, Hitachi is also involved in therapy equipment including particle beam systems, X-ray systems and cryoablation treatment systems.

Within oncology, is Hitachi’s collaboration with Hokkaido University, Japan, where the university’s motion tracking technology combines with Hitachi’s spot scanning irradiation technology to allow tumours to be moved precisely.

Clearly, the global healthcare market is undergoing a major transformation; by harnessing exciting developments in personalization, digitisation, wellness and patient engagement, businesses and health services can certainly help to improve our lives. With the industry facing a number of pressing challenges, now is the time to use this technology to really make a difference.

Innovations for the future

Modern life is saturated with data, and new technologies are emerging nearly every day – but how can we use these innovations to make a real difference to the world?

Hitachi believes that Social Innovation should underpin everything they do, so they can find ways to tackle the biggest issues we face today.

Visit social-innovation.hitachi to learn how Social Innovation is helping Hitachi drive change across the globe.

Source: http://www.telegraph.co.uk/business/social-innovation/smart-health-technology/

Philips unveils new image-guided therapies and diagnostic devices by Danielle Kirsh

Philips is showcasing some of its recently expanded image-guided therapies at the annual Transcatheter Cardiovascular Therapeutics (TCT) event in Denver this year. The company is touting its advanced interventional imaging systems, diagnostic a…

Philips is showcasing some of its recently expanded image-guided therapies at the annual Transcatheter Cardiovascular Therapeutics (TCT) event in Denver this year.

 

The company is touting its advanced interventional imaging systems, diagnostic and therapeutic devices, planning and navigation software and various services. It is also showcasing its latest cardiac care solutions for ultrasound and image-guided therapy. Its Dynamic coronary Roadmap 2.0 with FFR/IFR Roadmap is also on display at the event.

Medtech giant Royal Philips has been working on image-guided therapies for the last year, hoping to create cost-effective healthcare. The company released its Azurion imaging platform for low-dosage X-rays along with its augmented reality (AR) surgical navigation technology earlier this year. Philips suggests that image-guided therapies can help bring a more personalized treatment system to patients.

A combination of imaging systems, interventional devices, navigation tools and patient health records helps Philips’s Azurion give physicians the control and information they need to curb cardiovascular disease, according to the company.

Interventional X-ray systems from Philips are joined by the company’s new and next-generation 3D TEE technology that allows physicians to have a new level of live 3D imaging. It has a new acoustic design that features higher frequencies and bandwidth to allow for better resolution and tissue fitting.

The company has also launched its diagnostic device, the Refinity ST next-generation rotational intravascular ultrasound (IVUS) catheter. It features exceptional deliverability, 5F guide compatibility and 45 MHz high-resolution imaging. Refinity ST helps clinicians with complex percutaneous coronary interventional cases.

Philips’s CoreVision iFR co-registration solution and the CoreIVUS and physiology technology helps physicians in the stunting process when lesions are more complex.

Philips is also touting its Stellarex drug-coated balloon therapeutic device at TCT this year. It is the only commercially-available drug-coated balloon and has been shown to have durability and consistently high potency rates in a variety of patients.

“TCT provides the opportunity for us to share our expanded portfolio that aims to help those affected by cardiovascular disease to get back to living their lives,” Bert van Meurs, business leader of Image Guided Therapy for Philips, said in a press release. “At the congress this year, we’ll demonstrate how we’re furthering our goal to help clinicians decide, guide, treat and confirm the right therapies for their patients and provide safe and personalized treatments to enable faster recoveries while reducing costs.”

The company is presenting its technology at booths 1029 and 4133 at TCT in Denver, Oct. 29 through Nov. 2.

 

Source: http://www.medicaldesignandoutsourcing.com/philips-unveils-new-image-guided-therapies-diagnostic-devices/

Digital health technologies can reinvigorate the aged population by Dave Muoio

Kvedar.jpg

It’s hard to argue that steadily increasing lifespans are anything but a positive, but medical breakthroughs over the past few decades have brought with them another pressing challenge for digital health to overcome: aging.

“We’re not getting any younger, either individually or as a society. In fact, for the first time in history, by 2020 there’ll be more people over 65 than under five,” Dr. Joseph Kvedar, vice president, Connected Health, Partners Healthcare, said during his keynote presentation at the Connected Health Conference in Boston. “Why do I bring up those statistics to point out the challenge? Because every time we do care delivery … we’re doing it one-to-one. You’re all really bright people, you can do the math. We’re going to run out of people to deliver care if we don’t think about doing it differently.”

In his talk, Kvedar said that for centuries healthcare has always relied on the young to provide care and support for their elders. As the latter population grows, however, digital technologies may become especially necessary to mass-deliver personalized care, and to help the aging population maintain their good health.

Among the first steps to doing so is to get over tech’s perception that those over the age of 50 can’t use or understand new technologies, he argued. This demographic still generates billions of dollars to the economy, are twice as likely to start a new business than those who are younger, and provided an experienced perspective on complex issues, he said. Even those just 15 years older who qualify for social security are more and more often still capable of working, he noted.

For this group, new technologies outside of the healthcare space are already fulfilling needs. Research has shown that the aged population is more likely to lead longer, healthier lives if they have ample social connectivity, physical activity, and a sense of purpose, Kvedar explained. Already, social media, fitness wearables, and other technologies are being adopted by older demographics to fulfill these gaps, and for the most part healthcare still hasn’t taken notice.

“Think about all the opportunities you have now to go online and sign up for some kind of program, website, et cetera, where you can offer your services,” he said. “I’m going to sign up to be a mentor, to be a consultant, to give back from 4:00 to 6:00 on Tuesday and Thursday afternoons, whatever it may be. The internet and mobile has allowed us to be able to deliver services wherever and whenever in such a way that we can still feel retired and able to give back … we have to be able to build that into public health, have to build that into our policies, build that into the way we think that technology really has a role to play.”

However, the aged population’s more direct need for technology comes in the form of chronic disease or other life-threatening disease care. Here, Kvedar returned to his opening points on the unavoidable need for new care delivery options, and offered currently available remote care technologies as a solution.

Delivery of chronic care is real challenge because as healthcare professionals we just think that you have to come into the office, and most patients and consumers just think that they have to come into the office,” he said. “But we all know [that with remote care monitoring technology] you can have one care provider managing by exception, managing hundreds of individuals. And if you set it up right, they will feel more cared for, they will feel more connected. We’ve seen this in our own programs.”

Kvedar noted that there are several products already being developed commercially for in-home aging care, such as Catalia Health’s Mabu personal robot, Hasbro’s interactive companion cats, and various video consultation services. Despite some caveats, he said that these solutions are continuously becoming cheaper and more “human,” and should be continually pursued to bring better care to a growing population.

“None of these should ever be used to substitute a human connection. That’s a bad use of any of these technologies,” he said. “But when you can’t be with your love one because you have a life, and in a care facility when you just can’t have enough people to get around, if these things are thoughtfully designed and brought in they will be able to drive home that connected care feeling that individuals will need when they get older. We have to design that right.”

 

 

Source: http://www.mobihealthnews.com/content/digital-health-technologies-can-reinvigorate-aged-population